共 45 条
- [41] Impact of Programmed Death-Ligand 1 (PD-L1) Expression on The Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E137 - E137
- [43] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1) JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
- [44] AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1). JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)